

**In th Claims:**

Claims 1-50 (Cancelled)

51. (Currently Amended) ~~The method according to any one of claims 43-47~~ A method for reducing immune-mediated damage to cells, tissues or organs comprising contacting a cell, tissue or organ with an immunoprotective amount of polypeptide comprising the amino acid sequence AVLSAEQLR (SEQ ID NO:3), wherein the immune-mediated damage is caused by CIK cells.

Claims 52-59 (Cancelled)

60. (New) A method for protecting cells, organs or tissues comprising exposing said cells, organs or tissues to an immunoprotective amount of an Hsp47-related polypeptide to prevent damage caused by lymphocytes, NK cells or NK-like cells.

61. (New) The method of claim 60, wherein said Hsp47-related polypeptide comprises the sequence AX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>AX<sub>4</sub>X<sub>5</sub>X<sub>6</sub>R, wherein X<sub>1</sub> is V, L, A or T, X<sub>2</sub> is L or H, X<sub>3</sub> is S or V, X<sub>4</sub> is D or E, X<sub>5</sub> is Q, K or R, and X<sub>6</sub> is L or V (SEQ ID NO:1).

62. (New) The method of claim 60, wherein said Hsp47-related polypeptide comprises the sequence AX<sub>1</sub>LSAEX<sub>5</sub>X<sub>6</sub>R wherein X<sub>1</sub> is V, L or T, X<sub>5</sub> is Q, K or R, and X<sub>6</sub> is L or V (SEQ ID NO:14).

63. (New) The method of claim 60, wherein said Hsp47-related polypeptide comprises the sequence AX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>AEQLR, wherein X<sub>1</sub>, X<sub>2</sub> and X<sub>3</sub> are any amino acid.

64. (New) The method of claim 63, wherein X<sub>1</sub> is V or A, X<sub>2</sub> is L or H, and X<sub>3</sub> is preferably S or V (SEQ ID NO:2).

65. (New) The method of claim 60, wherein said Hsp47-related polypeptide comprises the sequence AVLSAX<sub>4</sub>X<sub>5</sub>LR wherein X<sub>4</sub> is D or E, and X<sub>5</sub> is K or Q (SEQ ID NO:13).

66. (New) A method for protecting cells, organs or tissues comprising exposing said cells, organs or tissues to an immunoprotective amount of an Hsp47 polypeptide to prevent damage caused by lymphocytes, NK cells or NK-like cells.

67. (New) The method of claim 66, wherein said Hsp47 polypeptide comprises the sequence AVLSAEQLR (SEQ ID NO:3).

68. (New) The method of claim 66, wherein said Hsp47 polypeptide consists essentially of the sequence AVLSAEQLR (SEQ ID NO:3).

69. (New) The method of claim 66, wherein said Hsp47 polypeptide comprises a sequence at least 70% identical to SEQ ID NO:6.

70. (New) The method of claim 66, wherein said Hsp47 polypeptide comprises a sequence at least 80% identical to SEQ ID NO:6.

71. (New) The method of claim 66, wherein said Hsp47 polypeptide comprises a sequence at least 90% identical to SEQ ID NO:6.

72. (New) The method of claim 66, wherein said Hsp47 polypeptide comprises a sequence at least 95% identical to SEQ ID NO:6.

73. (New) The method of claim 66, wherein said Hsp47 polypeptide consists of SEQ ID NO:6.

74. (New) The method of claim 66, wherein said Hsp47 polypeptide comprises a sequence at least 70% identical to SEQ ID NO:3.

75. (New) The method of claim 66, wherein said Hsp47 polypeptide comprises a sequence at least 80% identical to SEQ ID NO:3.

76. (New) The method of claim 66, wherein said Hsp47 polypeptide comprises a sequence at least 90% identical to SEQ ID NO:3.

77. (New) The method of claim 66, wherein said Hsp47 polypeptide comprises a sequence at least 95% identical to SEQ ID NO:3.

78. (New) The method of claim 66, wherein said Hsp47 polypeptide comprises a polypeptide encoded by a nucleic acid sequence which hybridizes with a nucleic acid sequence of SEQ ID NO:4.